Literature DB >> 11850839

Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.

David N Reisman1, Matthew W Strobeck, Bryan L Betz, Janiece Sciariotta, William Funkhouser, Christian Murchardt, Moshe Yaniv, Larry S Sherman, Erik S Knudsen, Bernard E Weissman.   

Abstract

Mammalian cells express two homologs of the SWI2 subunit of the SWI/SNF chromatin-remodeling complex called BRG1 and BRM. Whether the SWI/SNF complexes formed by these two subunits perform identical or different functions remains an important question. In this report, we show concomitant down-regulation of BRG1 and BRM in six human tumor cell lines. This down-regulation occurs at the level of mRNA abundance. We tested whether BRM could affect aberrant cellular functions attributed to BRG1 in tumor cell lines. By transient transfection, we found that BRM can restore RB-mediated cell cycle arrest, induce expression of CD44 protein and suppress Cyclin A expression. Therefore, BRM may be consistently down-regulated with BRG1 during neoplastic progression because they share some redundant functions. However, assorted tissues from BRM null/BRG1-positive mice lack CD44 expression, suggesting that BRM-containing SWI/SNF complexes regulate expression of this gene under physiological conditions. Our studies further define the mechanism by which chromatin-remodeling complexes participate in RB-mediated cell cycle arrest and provide additional novel evidence that the functions of SWI/SNF complexes containing BRG1 or BRM are not completely interchangeable.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850839     DOI: 10.1038/sj.onc.1205188

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  68 in total

1.  Growth inhibition by the mammalian SWI-SNF subunit Brm is regulated by acetylation.

Authors:  Brigitte Bourachot; Moshe Yaniv; Christian Muchardt
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

2.  Role for BRG1 in cell cycle control and tumor suppression.

Authors:  Kristin B Hendricks; Frances Shanahan; Emma Lees
Journal:  Mol Cell Biol       Date:  2004-01       Impact factor: 4.272

Review 3.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins.

Authors:  Alea A Mills
Journal:  Nat Rev Cancer       Date:  2010-10       Impact factor: 60.716

4.  Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.

Authors:  Anbarasi Kothandapani; Kathirvel Gopalakrishnan; Bhaskar Kahali; David Reisman; Steve M Patrick
Journal:  Exp Cell Res       Date:  2012-06-18       Impact factor: 3.905

Review 5.  Diverse regulation of 3' splice site usage.

Authors:  Muhammad Sohail; Jiuyong Xie
Journal:  Cell Mol Life Sci       Date:  2015-09-14       Impact factor: 9.261

6.  SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells.

Authors:  Nathalie Cohet; Kathleen M Stewart; Rajini Mudhasani; Ananthi J Asirvatham; Chandrashekara Mallappa; Karen M Imbalzano; Valerie M Weaver; Anthony N Imbalzano; Jeffrey A Nickerson
Journal:  J Cell Physiol       Date:  2010-06       Impact factor: 6.384

7.  Transcriptional coactivators are not required for herpes simplex virus type 1 immediate-early gene expression in vitro.

Authors:  Sebla B Kutluay; Sarah L DeVos; Jennifer E Klomp; Steven J Triezenberg
Journal:  J Virol       Date:  2009-01-28       Impact factor: 5.103

Review 8.  Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer.

Authors:  Bernard Weissman; Karen E Knudsen
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

9.  BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.

Authors:  Kevin A Link; Craig J Burd; Erin Williams; Thomas Marshall; Gary Rosson; Erin Henry; Bernard Weissman; Karen E Knudsen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

Review 10.  Chromatin-modifying enzymes as therapeutic targets--Part 2.

Authors:  Brian R Keppler; Trevor K Archer
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.